Symbols / COLL Stock $34.87 -2.30% Collegium Pharmaceutical, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
COLL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Vikram Karnani
Exch · Country NMS · United States
Market Cap 1.13B
Enterprise Value 1.64B
Income 74.95M
Sales 796.33M
FCF (ttm) 332.62M
Book/sh 9.64
Cash/sh 13.00
Employees 423
Insider 10d —
IPO May 07, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 16.93
Forward P/E 4.90
PEG —
P/S 1.42
P/B 3.62
P/C —
EV/EBITDA 3.86
EV/Sales 2.06
Quick Ratio 1.50
Current Ratio 1.71
Debt/Eq 297.57
LT Debt/Eq —
EPS (ttm) 2.06
EPS next Y 7.11
EPS Growth -46.60%
Revenue Growth 8.90%
EPS Gr Q/Q 5.00%
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA 7.60%
ROE 27.41%
ROIC —
Gross Margin 89.17%
Oper. Margin 15.96%
Profit Margin 9.41%
Shs Outstand 32.43M
Shs Float 32.06M
Insider Own 0.94%
Instit Own 120.61%
Short Float 21.88%
Short Ratio 11.76
Short Interest 5.94M
52W High 50.79
vs 52W High -31.34%
52W Low 28.34
vs 52W Low 23.05%
Beta 0.76
Impl. Vol. 0.78%
Rel Volume 1.16
Avg Volume 548.20K
Volume 633.61K
Target (mean) $54.33
Tgt Median $56.00
Tgt Low $45.00
Tgt High $60.00
# Analysts 6
Recom Buy
Prev Close $35.69
Price $34.87
Change -2.30%
About

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$54.33
Mean price target
2. Current target
$34.87
Latest analyst target
3. DCF / Fair value
$184.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$34.87
Low
$45.00
High
$60.00
Mean
$54.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 reit HC Wainwright & Co. Buy → Buy $60
2026-03-19 reit Needham Buy → Buy $56
2026-02-26 main Needham Buy → Buy $54
2026-01-09 main Barclays Overweight → Overweight $56
2026-01-09 reit HC Wainwright & Co. Buy → Buy $60
2026-01-08 main Needham Buy → Buy $56
2025-12-09 init Barclays — → Overweight $58
2025-11-07 main Truist Securities Buy → Buy $48
2025-11-07 main HC Wainwright & Co. Buy → Buy $46
2025-10-28 reit Needham Buy → Buy $46
2025-05-09 reit Piper Sandler Neutral → Neutral $37
2025-04-09 reit Needham Buy → Buy $46
2025-03-24 reit HC Wainwright & Co. Buy → Buy $50
2025-02-04 main Piper Sandler Neutral → Neutral $36
2025-01-10 up Needham Hold → Buy $46
2025-01-10 reit HC Wainwright & Co. Buy → Buy $50
2024-10-11 reit Piper Sandler Neutral → Neutral $37
2024-09-05 main HC Wainwright & Co. Buy → Buy $50
2024-08-09 reit Piper Sandler Neutral → Neutral $37
2024-08-09 main Truist Securities Buy → Buy $42
News
RSS: Latest COLL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-18 DIETER DAVID General Counsel — 13,976 $34.92 $488,099
2026-03-09 DIETER DAVID General Counsel — 6,224 $36.65 $228,110
2026-03-03 DREYER SCOTT Officer — 49,976 $40.36 $2,019,437
2026-02-10 DREYER SCOTT Officer — 49,725 $0.00 $0
2026-02-10 SMITH THOMAS BRAIN M.D. Officer — 37,042 $0.00 $0
2026-02-10 TUPPER COLLEEN Chief Financial Officer — 59,155 $0.00 $0
2026-02-10 DIETER DAVID General Counsel — 31,199 $0.00 $0
2026-02-10 KARNANI VIKRAM Chief Executive Officer — 111,795 $0.00 $0
2025-12-08 DREYER SCOTT Officer — 17,600 $47.89 $847,855
2025-12-08 DREYER SCOTT Officer — 17,600 $15.90 $279,840
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
780.57
+23.62%
631.45
+11.41%
566.77
+22.17%
463.93
Operating Revenue
780.57
+23.62%
631.45
+11.41%
566.77
+22.17%
463.93
Cost Of Revenue
317.31
+24.87%
254.10
+5.61%
240.60
-5.44%
254.44
Reconciled Cost Of Revenue
317.31
+24.87%
254.10
+5.61%
240.60
-5.44%
254.44
Gross Profit
463.26
+22.77%
377.34
+15.69%
326.17
+55.70%
209.49
Operating Expense
284.80
+35.39%
210.36
+32.13%
159.21
-9.63%
176.17
Research And Development
—
0.00
0.00
-100.00%
3.98
Selling General And Administration
284.80
+35.39%
210.36
+32.13%
159.21
-7.54%
172.19
Total Expenses
602.11
+29.63%
464.47
+16.17%
399.81
-7.15%
430.61
Operating Income
178.45
+6.87%
166.98
+0.01%
166.96
+401.10%
33.32
Total Operating Income As Reported
179.64
+5.73%
169.90
+1.76%
166.96
+401.10%
33.32
EBITDA
401.00
+17.36%
341.70
+10.82%
308.33
+77.91%
173.31
Normalized EBITDA
415.82
+18.77%
350.12
+5.51%
331.83
+91.47%
173.31
Reconciled Depreciation
226.07
+33.65%
169.16
+13.34%
149.26
+7.43%
138.94
EBIT
174.93
+1.38%
172.54
+8.47%
159.07
+362.88%
34.37
Total Unusual Items
-14.81
-76.02%
-8.41
+64.20%
-23.50
0.00
Total Unusual Items Excluding Goodwill
-14.81
-76.02%
-8.41
+64.20%
-23.50
0.00
Special Income Charges
-14.81
-76.02%
-8.41
+64.20%
-23.50
0.00
Other Special Charges
15.99
+41.18%
11.33
-51.80%
23.50
—
Restructuring And Mergern Acquisition
-1.18
+59.44%
-2.91
0.00
0.00
Net Income
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Pretax Income
92.62
-6.04%
98.57
+30.15%
75.73
+362.53%
-28.85
Net Non Operating Interest Income Expense
-71.02
-18.38%
-60.00
+11.41%
-67.72
-8.94%
-62.17
Interest Expense Non Operating
82.31
+11.27%
73.97
-11.24%
83.34
+31.84%
63.21
Net Interest Income
-71.02
-18.38%
-60.00
+11.41%
-67.72
-8.94%
-62.17
Interest Expense
82.31
+11.27%
73.97
-11.24%
83.34
+31.84%
63.21
Interest Income Non Operating
11.29
-19.23%
13.98
-10.50%
15.62
+1391.40%
1.05
Interest Income
11.29
-19.23%
13.98
-10.50%
15.62
+1391.40%
1.05
Other Income Expense
-14.81
-76.02%
-8.41
+64.20%
-23.50
—
Tax Provision
29.75
+1.26%
29.38
+6.53%
27.58
+817.24%
-3.85
Tax Rate For Calcs
0.00
+7.72%
0.00
-18.13%
0.00
+173.68%
0.00
Tax Effect Of Unusual Items
-4.75
-89.60%
-2.51
+70.69%
-8.56
0.00
Net Income Including Noncontrolling Interests
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Net Income From Continuing Operation Net Minority Interest
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Net Income From Continuing And Discontinued Operation
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Net Income Continuous Operations
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Normalized Income
72.93
-2.89%
75.10
+19.01%
63.10
+352.39%
-25.00
Net Income Common Stockholders
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Diluted EPS
1.73
-6.99%
1.86
+44.19%
1.29
+274.32%
-0.74
Basic EPS
1.98
-7.48%
2.14
+49.65%
1.43
+293.24%
-0.74
Basic Average Shares
31.71
-1.76%
32.27
-4.35%
33.74
-0.26%
33.83
Diluted Average Shares
39.70
-1.79%
40.42
-3.26%
41.79
+23.53%
33.83
Diluted NI Availto Com Stockholders
68.88
-8.23%
75.05
+38.87%
54.04
+316.16%
-25.00
Average Dilution Earnings
6.01
+2.46%
5.86
-0.44%
5.89
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,656.83
-0.41%
1,663.59
+45.51%
1,143.31
-2.63%
1,174.13
Current Assets
691.41
+43.37%
482.26
-10.29%
537.60
+28.00%
419.99
Cash Cash Equivalents And Short Term Investments
386.68
+137.57%
162.76
-47.59%
310.55
+78.80%
173.69
Cash And Cash Equivalents
231.25
+227.71%
70.56
-70.47%
238.95
+37.57%
173.69
Other Short Term Investments
155.43
+68.58%
92.20
+28.77%
71.60
0.00
Receivables
211.33
-7.53%
228.54
+27.30%
179.53
-1.96%
183.12
Accounts Receivable
211.33
-7.53%
228.54
+27.30%
179.53
-1.96%
183.12
Inventory
40.91
+15.05%
35.56
+9.98%
32.33
-30.47%
46.50
Raw Materials
—
—
10.38
+85.43%
5.60
Work In Process
—
—
6.74
-72.68%
24.67
Finished Goods
—
—
15.21
-6.29%
16.23
Prepaid Assets
29.40
+6.33%
27.65
+83.10%
15.10
-9.16%
16.62
Restricted Cash
19.85
-20.60%
25.00
0.00
—
Other Current Assets
3.24
+18.13%
2.74
+2848.39%
0.09
+63.16%
0.06
Total Non Current Assets
965.42
-18.28%
1,181.33
+95.03%
605.71
-19.68%
754.14
Net PPE
16.20
-19.61%
20.15
-8.45%
22.01
-16.56%
26.38
Gross PPE
32.74
-2.80%
33.69
+6.30%
31.69
-3.10%
32.70
Accumulated Depreciation
-16.54
-22.23%
-13.53
-39.84%
-9.68
-53.06%
-6.32
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
3.99
-13.07%
4.59
+30.39%
3.52
-2.84%
3.62
Construction In Progress
1.75
+117.71%
0.80
0.00
0.00
Other Properties
25.77
-4.76%
27.06
-0.17%
27.11
-3.90%
28.21
Leases
1.23
+0.00%
1.23
+16.02%
1.06
+21.40%
0.87
Goodwill And Other Intangible Assets
815.43
-22.61%
1,053.73
+89.67%
555.57
-20.77%
701.16
Goodwill
145.93
-10.11%
162.33
+21.27%
133.86
+0.12%
133.69
Other Intangible Assets
669.51
-24.89%
891.40
+111.38%
421.71
-25.69%
567.47
Non Current Deferred Assets
112.54
+14.80%
98.03
+273.33%
26.26
+9.64%
23.95
Non Current Deferred Taxes Assets
112.54
+14.80%
98.03
+273.33%
26.26
+9.64%
23.95
Other Non Current Assets
21.25
+125.69%
9.41
+402.94%
1.87
-29.28%
2.65
Total Liabilities Net Minority Interest
1,355.16
-5.55%
1,434.75
+51.36%
947.88
-3.21%
979.29
Current Liabilities
440.03
-13.64%
509.51
+11.27%
457.92
+5.58%
433.73
Payables And Accrued Expenses
402.81
-7.62%
436.05
+60.18%
272.22
+1.34%
268.61
Payables
39.25
-18.35%
48.08
+203.48%
15.84
+101.90%
7.85
Accounts Payable
10.66
+170.95%
3.93
-54.74%
8.69
+148.77%
3.49
Other Payable
17.57
-39.34%
28.96
—
—
Current Accrued Expenses
363.55
-6.29%
387.97
+51.33%
256.38
-1.68%
260.76
Pensionand Other Post Retirement Benefit Plans Current
3.71
-18.62%
4.56
+231.93%
1.38
-8.76%
1.51
Total Tax Payable
11.03
-27.37%
15.19
+112.41%
7.15
+64.27%
4.35
Income Tax Payable
3.30
-61.33%
8.53
+299.11%
2.14
0.00
Current Debt And Capital Lease Obligation
30.41
-53.83%
65.85
-64.27%
184.32
+12.66%
163.61
Current Debt
29.00
-55.10%
64.58
-64.77%
183.33
+12.82%
162.50
Other Current Borrowings
29.00
-55.10%
64.58
-64.77%
183.33
+12.82%
162.50
Current Capital Lease Obligation
1.41
+10.70%
1.27
+28.64%
0.99
-11.15%
1.11
Current Deferred Liabilities
0.67
0.00
—
—
Current Deferred Revenue
0.67
0.00
—
—
Other Current Liabilities
2.44
-20.01%
3.04
—
—
Total Non Current Liabilities Net Minority Interest
915.13
-1.09%
925.24
+88.84%
489.96
-10.19%
545.56
Long Term Debt And Capital Lease Obligation
784.46
-1.13%
793.44
+61.94%
489.96
-10.19%
545.56
Long Term Debt
780.33
-0.96%
787.90
+62.84%
483.84
-10.14%
538.45
Long Term Capital Lease Obligation
4.13
-25.40%
5.54
-9.55%
6.12
-13.89%
7.11
Non Current Deferred Liabilities
130.67
+0.05%
130.61
0.00
—
Non Current Deferred Revenue
9.11
-8.89%
10.00
0.00
—
Other Non Current Liabilities
—
1.18
—
—
Stockholders Equity
301.68
+31.83%
228.84
+17.10%
195.43
+0.30%
194.84
Common Stock Equity
301.68
+31.83%
228.84
+17.10%
195.43
+0.30%
194.84
Capital Stock
0.04
+2.50%
0.04
+5.26%
0.04
+2.70%
0.04
Common Stock
0.04
+2.50%
0.04
+5.26%
0.04
+2.70%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
40.74
+2.75%
39.65
+3.81%
38.19
+2.99%
37.08
Ordinary Shares Number
31.71
+0.85%
31.44
-1.34%
31.87
-5.85%
33.85
Treasury Shares Number
9.03
+10.02%
8.21
+29.77%
6.32
+95.43%
3.24
Additional Paid In Capital
624.95
+5.88%
590.25
+4.29%
565.95
+5.18%
538.07
Retained Earnings
-101.13
+38.34%
-164.00
+29.67%
-233.19
+17.12%
-281.34
Gains Losses Not Affecting Retained Earnings
0.32
+480.00%
0.06
+292.86%
0.01
0.00
Treasury Stock
222.51
+12.66%
197.50
+43.76%
137.38
+121.85%
61.92
Other Equity Adjustments
0.32
+480.00%
0.06
+292.86%
0.01
—
Total Equity Gross Minority Interest
301.68
+31.83%
228.84
+17.10%
195.43
+0.30%
194.84
Total Capitalization
1,082.00
+6.42%
1,016.75
+49.68%
679.27
-7.37%
733.29
Working Capital
251.38
+1022.40%
-27.25
-134.20%
79.69
+680.08%
-13.74
Invested Capital
1,111.00
+2.74%
1,081.33
+25.36%
862.60
-3.71%
895.79
Total Debt
814.86
-5.17%
859.30
+27.44%
674.28
-4.92%
709.17
Net Debt
578.07
-26.07%
781.92
+82.60%
428.22
-18.78%
527.26
Capital Lease Obligations
5.54
-18.66%
6.81
-4.25%
7.11
-13.52%
8.22
Net Tangible Assets
-513.76
+37.72%
-824.89
-129.05%
-360.13
+28.87%
-506.32
Tangible Book Value
-513.76
+37.72%
-824.89
-129.05%
-360.13
+28.87%
-506.32
Interest Payable
12.02
+95.62%
6.15
+115.42%
2.85
+102.34%
1.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
329.32
+60.66%
204.98
-25.39%
274.75
+121.16%
124.23
Cash Flow From Continuing Operating Activities
329.32
+60.66%
204.98
-25.39%
274.75
+121.16%
124.23
Net Income From Continuing Operations
62.87
-9.13%
69.19
+43.68%
48.16
+292.60%
-25.00
Depreciation Amortization Depletion
226.07
+33.65%
169.16
+13.34%
149.26
+7.43%
138.94
Depreciation
4.18
+8.45%
3.86
+10.30%
3.50
+30.25%
2.68
Amortization Cash Flow
221.89
+34.23%
165.30
+13.41%
145.76
+6.98%
136.25
Depreciation And Amortization
226.07
+33.65%
169.16
+13.34%
149.26
+7.43%
138.94
Amortization Of Intangibles
221.89
+34.23%
165.30
+13.41%
145.76
+6.98%
136.25
Other Non Cash Items
5.45
-18.94%
6.72
-19.56%
8.36
-1.97%
8.52
Stock Based Compensation
41.91
+29.34%
32.40
+19.40%
27.14
+18.63%
22.87
Deferred Tax
-25.66
+4.31%
-26.81
-1145.42%
-2.15
+74.34%
-8.39
Deferred Income Tax
-25.66
+4.31%
-26.81
-1145.42%
-2.15
+74.34%
-8.39
Operating Gains Losses
15.99
+41.18%
11.33
-51.80%
23.50
—
Change In Working Capital
3.76
+106.84%
-54.98
-352.99%
21.73
+270.94%
-12.71
Change In Receivables
17.20
+489.76%
-4.41
-222.82%
3.59
+116.50%
-21.78
Changes In Account Receivables
17.20
+489.76%
-4.41
-222.82%
3.59
+116.50%
-21.78
Change In Inventory
-5.35
-138.44%
13.93
-1.71%
14.17
-70.65%
48.27
Change In Prepaid Assets
-7.97
+43.37%
-14.07
-1077.76%
1.44
+131.24%
-4.61
Change In Payables And Accrued Expense
0.07
+100.15%
-50.42
-2093.71%
2.53
+107.31%
-34.60
Change In Accrued Expense
-6.64
+83.03%
-39.14
-1445.93%
-2.53
+92.53%
-33.90
Change In Payable
6.72
+159.57%
-11.28
-322.84%
5.06
+815.84%
-0.71
Change In Account Payable
6.72
+159.57%
-11.28
-322.84%
5.06
+815.84%
-0.71
Change In Other Working Capital
-0.20
—
—
0.00
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
-63.53
+77.92%
-287.76
-306.37%
-70.81
+87.66%
-573.69
Cash Flow From Continuing Investing Activities
-63.53
+77.92%
-287.76
-306.37%
-70.81
+87.66%
-573.69
Net PPE Purchase And Sale
-1.74
-5.33%
-1.65
-258.35%
-0.46
+71.58%
-1.62
Purchase Of PPE
-1.74
-5.33%
-1.65
-258.35%
-0.46
+71.58%
-1.62
Capital Expenditure
-1.74
-5.33%
-1.65
-258.35%
-0.46
+71.58%
-1.62
Net Investment Purchase And Sale
-61.79
-232.77%
-18.57
+73.61%
-70.35
0.00
Purchase Of Investment
-126.97
-14.21%
-111.17
-20.38%
-92.35
0.00
Sale Of Investment
65.18
-29.62%
92.60
+320.92%
22.00
0.00
Net Business Purchase And Sale
0.00
+100.00%
-267.54
0.00
+100.00%
-572.07
Purchase Of Business
0.00
+100.00%
-267.54
0.00
+100.00%
-572.07
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
-110.25
-81.91%
-60.60
+56.77%
-140.18
-132.10%
436.72
Cash Flow From Continuing Financing Activities
-110.25
-81.91%
-60.60
+56.77%
-140.18
-132.10%
436.72
Net Issuance Payments Of Debt
-70.38
-1036.07%
7.52
+111.41%
-65.92
-114.89%
442.68
Issuance Of Debt
565.17
+80.47%
313.18
+33.14%
235.22
-54.56%
517.68
Repayment Of Debt
-635.56
-107.93%
-305.66
-1.50%
-301.14
-301.52%
-75.00
Long Term Debt Issuance
565.17
+80.47%
313.18
+33.14%
235.22
-54.56%
517.68
Long Term Debt Payments
-635.56
-107.93%
-305.66
-1.50%
-301.14
-301.52%
-75.00
Net Long Term Debt Issuance
-70.38
-1036.07%
7.52
+111.41%
-65.92
-114.89%
442.68
Net Common Stock Issuance
-25.10
+58.18%
-60.02
+19.97%
-75.00
-433.31%
-14.06
Common Stock Payments
-25.10
+58.18%
-60.02
+19.97%
-75.00
-433.31%
-14.06
Repurchase Of Capital Stock
-25.10
+58.18%
-60.02
+19.97%
-75.00
-433.31%
-14.06
Proceeds From Stock Option Exercised
5.64
-49.04%
11.07
+21.67%
9.10
-25.08%
12.15
Net Other Financing Charges
-20.40
-6.42%
-19.17
-129.28%
-8.36
-106.75%
-4.04
Changes In Cash
155.55
+208.48%
-143.38
-324.88%
63.76
+600.54%
-12.74
Beginning Cash Position
96.61
-59.74%
239.99
+36.18%
176.24
-6.74%
188.97
End Cash Position
252.16
+161.00%
96.61
-59.74%
239.99
+36.18%
176.24
Free Cash Flow
327.58
+61.11%
203.33
-25.87%
274.29
+123.71%
122.61
Interest Paid Supplemental Data
68.76
+10.13%
62.43
-14.77%
73.26
+39.46%
52.53
Income Tax Paid Supplemental Data
60.04
+15.26%
52.09
+115.20%
24.20
+132.74%
10.40
Amortization Of Securities
-1.07
+47.14%
-2.03
-64.21%
-1.24
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category